European Commission Approves Extended Indication For Amgen's Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients

Head-to-Head Phase 3 Trial Demonstrated Superiority of Kyprolis and Dexamethasone Over Velcade® (Bortezomib) and Dexamethasone in Patients with Relapsed Multiple Myeloma New Indication Allows Kyprolis to be Used in Combination with Dexamethasone Alone for Appropriate Patients

Amgen - Investors - RSS Content